It was already reported in breast and prostate cancer cell lines, that IL-6-mediated STAT3 activation showed to be RKIP-dependent as it was demonstrated by the lack of STAT3 activation in a human breast carcinoma cell line overexpressing RKIP and a significant enhancement of activation in cells with RKIP knockdown [12]. This evidence concerns the gene STAT3 and prostate cancer.